Touchlight will join the global gene and cell therapy community at the ASGCT 2026 Annual Meeting, held May 11–15, 2026 at the Thomas M. Menino Convention & Exhibition Center in Boston, MA.

Visit us at booth # 1334

As a leader in cell‑free DNA manufacturing, Touchlight is shaping the next era of advanced therapy development. At ASGCT, our team will discuss how mbDNA and Custom Circles, our next‑generation, circular single‑stranded DNA formats, enable developers to move faster, overcome plasmid constraints, and streamline the path from discovery to clinic.

Throughout the meeting, our commercial and scientific experts will be onsite for discussions so if you’re attending ASGCT, we welcome you to connect with us to explore how Touchlight’s technology can accelerate your pipeline.

Schedule a meeting with one of our experts!

Touchlight is proud to be exhibiting at the ISCT 2026 Annual Meeting, taking place 6–9 May in Dublin. As one of the field’s leading global forums, ISCT brings together key decision‑makers and innovators shaping the future of cell and gene therapies. This year’s program showcases novel research, emerging data, and transformative ideas delivered by global key opinion leaders.

Our Presence
Touchlight will be exhibiting at Booth# 1713 and presenting our latest abstract: “Reimagining DNA payloads: Enzymatic circular DNA for the next generation of cell and gene therapies.” This work highlights our continued commitment to innovating DNA formats that unlock new therapeutic possibilities. We look forward to sharing how our enzymatically produced suite of novel circular DNA architectures supports scalable, rapid, and regulatory‑aligned CGT development.

Interested in next‑generation DNA manufacturing? Request a meeting with a Touchlight expert today.

Touchlight Attendees

BIO KOREA 2026 is one of Asia’s leading biotechnology conventions, bringing together global biopharma companies, research institutions, investors, and innovators to explore emerging technologies and industry‑defining trends. Taking place 28–30 April 2026 at COEX Convention & Exhibition Center in Seoul, the event features an extensive program of exhibitions, partnering meetings, and expert‑led conferences focused on the rapidly evolving bio‑health landscape.

The Touchlight team will be onsite to discuss how our enzymatically produced doggybone DNA (dbDNA) is helping overcome the limitations of traditional plasmid DNA. As developers and suppliers of next‑generation, cell‑free DNA, we provide scalable, rapid, and regulatory‑aligned solutions that support solutions for gene therapy, vaccine platforms, and emerging genetic medicines.

Interested in next‑generation DNA manufacturing? Request a meeting with a Touchlight expert today.

Touchlight Attendees

The Cell & Gene Meeting on the Med is Europe’s leading advanced therapies conference, uniting ATMP decision‑makers for focused discussions on commercialization, regulatory strategy, manufacturing innovation, and sector financing. With expert‑led panels, dedicated partnering meetings, and presentations from organizations across the gene and cell therapy landscape, the event offers a high‑value forum for scientific and strategic engagement.

As a Silver Sponsor, Touchlight is proud to support this year’s meeting and the progress of the global advanced therapy community. We’ll be onsite to share how our enzymatically produced, next‑generation DNA provides faster, safer, and more scalable solutions for gene therapies, vaccines, mRNA platforms, and emerging modalities.

Interested in next‑generation DNA manufacturing? Request a meeting with a Touchlight expert today.

Touchlight Attendees

The British Society for Gene and Cell Therapy (BSGCT) Annual Conference is one of the UK’s leading forums for scientific exchange in advanced therapy development. Bringing together researchers, clinicians, industry innovators, and regulatory thinkers, the 2026 meeting will spotlight cutting‑edge progress in gene and cell therapy, translational research, and enabling technologies that support the next generation of advanced therapy medicinal products (ATMPs).

Touchlight attendees will be on site ready to talk with innovators seeking faster, safer, and more scalable DNA solutions for advanced therapies. As companies increasingly evaluate new approaches to gene editing, regulatory readiness, and manufacturing efficiency, dbDNA offers a next‑generation alternative to plasmid DNA that aligns with many of the conference’s core scientific and translational themes.

Interested in next‑generation DNA manufacturing? Request a meeting with a Touchlight expert at BSGCT 2026 to explore how dbDNA can support your upcoming programs.

Touchlight Attendees

The 3rd CRISPR MEDiCiNE Conference (CRISPRMED26) brings together the global CRISPR community in Copenhagen on 14–16 April 2026.

As the world’s largest international event focused on CRISPR medicine, the conference highlights cutting‑edge progress in genome editing, delivery technologies, functional genomics, regulatory insights, and clinical translation. For leaders advancing gene therapies, vaccines, and next‑generation genetic medicines, CRISPRMED26 offers unparalleled access.  The program features world‑class speakers, specialised workshops, dynamic poster sessions, and sessions dedicated to CMC, pre‑clinical and clinical pathways, and EU regulatory requirements—core considerations for organisations working toward scalable, compliant therapeutic development.

Touchlight will be on site to discuss how mbDNA, our circular single-stranded cell‑free DNA vector enables faster, safer, and more flexible development of CRISPR‑enabled therapies.

Interested in next‑generation DNA manufacturing? Request a meeting with a Touchlight expert today.

Touchlight Attendees